CD274 and hepatocellular carcinoma: The meta-analysis results showed that the combination of PD-1/PD-L1 inhibitors with TKIs significantly improved ORR (OR 3.17, P < 0.001), DCR (OR 2.44, P < 0.001), PFS (HR 0.58, P < 0.001), and OS (HR 0.58, P < 0.001) in HCC patients, which is consistent with the results observed in our study (32).